Status:

UNKNOWN

Dopamine D2 and D3 Receptor Occupancy and Clinical Response in Older Patients With Schizophrenia

Lead Sponsor:

Centre for Addiction and Mental Health

Conditions:

Schizophrenia

Schizoaffective Disorder

Eligibility:

All Genders

50+ years

Phase:

NA

Brief Summary

This study will provide information regarding dopamine D2/D3 occupancy related with clinical/adverse effects in older people with schizophrenia and schizoaffective disorder. The results of this study ...

Detailed Description

Positron Emission Tomography (PET) studies have demonstrated that a therapeutic window of dopamine D2/3 receptor occupancy (60-80%) is associated with clinical response in younger patients with schizo...

Eligibility Criteria

Inclusion

  • Age of 50 and older at time of scanning
  • Inpatients or outpatients
  • DSM-IV/SCID diagnosis of schizophrenia, schizoaffective disorder, or schizophreniform disorder
  • Having NOT been treated with oral antipsychotic treatment for at least 2 weeks or long-acting antipsychotics for at least 6 months (Please note that patients will not be withdrawn from antipsychotic medications for the purpose of meeting inclusion criteria for this study).

Exclusion

  • Known history of intolerance or inefficacy to risperidone
  • Participation in this study would result in exceeding the annual radiation dose limits (20 mSv) for human subjects participating in research studies.
  • Substance abuse or dependence (within past six months)
  • Positive urine drug screen
  • Positive serum pregnancy test at screening or positive urine pregnancy test before PET scan
  • Metal implants or a pace-maker that would preclude the MRI scan
  • History of head trauma resulting in loss of consciousness \>30 minutes that required medical attention
  • Unstable physical illness or significant neurological disorder including a seizure disorder
  • Inappropriate size of head, neck, and body to be able to fit the PET and MRI scans

Key Trial Info

Start Date :

December 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2020

Estimated Enrollment :

14 Patients enrolled

Trial Details

Trial ID

NCT00825045

Start Date

December 1 2008

End Date

December 1 2020

Last Update

February 7 2020

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Centre for Addiction and Mental Health

Toronto, Ontario, Canada, M5T 1R8